I just re-read the latest 10Q. We have a little Gem here. The fact that insiders own such a large percentage of shares reassures me that they will be looking out for the shareholders (or themselves)
Dr. Newsome discovered the link between subclinical zinc deficiency and Dry Age-Related Macular Degeneration (Dry AMD) With Bausch and Lomb and Alcon already marketing high-dose zinc supplementation you can bet that they are keeping a close EYE on the Adeona's progress. We have a an effective treatment being made better by the highly regarded doctor who discovered it.Decreased problems to stomach because of new delivery method. Add our ability for doctors to send out for tests at our Hartlab facility in Illinios Zinthionein could easily be the favored choice by MD's for dry AMD. Especially if someone like Alcon is interested (let me tell ya, they are watching)
Anyway, If you get a chance read the 10 Q. If you read up on our programs I think you will see that just one of our programs is enough to put our share price where it is today. In other words we are undervalued. We are going to be filing another IND also using Oral dnaJP1 (currently in the pipeline for RA)
So they are hoping to launch 1st quarter 2010
"Our sales and marketing plans include direct sales to physicians through a specialty sales force, promoting the understanding of chronic copper toxicity and zinc deficiency and patient education regarding the potential risks of chronic free copper exposure, and Through our Hart Lab CLIA-certified clinical reference laboratory, we are commercializing serum based diagnostic tests to assist physicians in identifying patients with zinc deficiency and patients at increased risk chronic copper toxicity due to impaired serum copper binding. Through our specialty sales force, we currently intend to launch Zinthionein™ ZC GS-150, our patent pending proposed once-daily gastro-retentive sustained release oral zinc preparation containing 150mg elemental zinc and the amino acid cysteine in the first quarter of 2010 as a prescription medical food for the dietary management of patients having conditions characterized by zinc deficiency and chronic copper toxicity, such as, Alzheimer’s disease and mild cognitive impairment (MCI). Through our Healthmine subsidiary, we launched copperproof.com, a website intended to increase public awareness aimed at the prevention of chronic copper toxicity. Our EyeDaily™ brand of oral zinc-based therapies is expected to utilize patent-pending product packaging that incorporates an eye-self test to improve compliance and convenience of patients with Dry AMD. "
I read this Motley fool article and can't help but think this is a stock OL buffet wished he could buy.